ClinicalTrials.gg
CompletedNCT02746796Updated May 3, 2024

Study of ONO-4538 in Gastric Cancer

A Phase 2/3 interventional study of ONO-4538 and Oxaliplatin in Gastric Cancer, sponsored by Ono Pharmaceutical Co. Ltd. Completed at 130 sites in 3 countries. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-05-03.

Sponsored by Ono Pharmaceutical Co. Ltd · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
680
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 30 studies testing nivolumab in Stomach Neoplasms — 6 open to participants now, 13 under way, 2 of them phase 3. Nivolumab · Stomach Neoplasms.

Planned enrollment
4th of 30
680 · median 49
Started
2016
with 2 others
Phase 2/3
Only one
of the 30
Registered
3rd of 30
by date
Lead sponsor
3 of 30
Ono Pharmaceutical Co. Ltd

Among the 30 studies testing nivolumab in Stomach Neoplasms, this one is the 4th largest by planned enrollment, is one of 3 that started in 2016, is the only one in phase 2/3, and was the 3rd registered.

Stomach Neoplasms

3,406 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

6 of the 30 studies testing nivolumab in Stomach Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 70 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing nivolumab in Stomach Neoplasms, or all of them as a file.
02

Study summary

The purpose of study is to evaluate the efficacy and safety of ONO-4538 with chemotherapy in unresectable advanced or recurrent gastric cancer (including esophagogastric junction cancer) not previously treated with the first-line therapy. Part 1 is intended to evaluate the tolerability, safety, and efficacy of ONO-4538 in combination with SOX therapy (Tegafur / gimeracil / oteracil potassium + Oxaliplatin) or CapeOX therapy (Capecitabine + Oxaliplatin). In part 2, the investigator or the subinvestigator will choose a chemotherapy (SOX or CapeOX therapy), taking into account the condition of each subject. Part 2 is planned to evaluate the efficacy and safety of ONO-4538 + chemotherapy in comparison with placebo + chemotherapy.

03

Conditions studied

  • Gastric Cancer

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with unresectable advanced or recurrent gastric cancer (including esophagogastric junction cancer) that has not been treated with the therapy with systemic antitumor agents for advanced or recurrent gastric cancer (including esophagogastric junction cancer)
  • Have as defined in Guideline Version 1.1
  • PS score 0 or 1
  • Have a of at least 3 months

Exclusion criteria

Exclusion Criteria:

  • Have multiple cancers
  • Have a current or past history of severe to any other antibody products
  • Patients with any in the brain or meninx that is symptomatic or requires treatment
  • Patients with active, known or suspected disease
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
680 participants (estimated)

Study arms

  • Experimental
    ONO-4538 + SOX Therapy Cohort (Part 1)

    ONO-4538 360 mg solution intravenously for 30 min in every 3 weeks. Oxaliplatin 130 mg/m2 (BSA) solution intravenously for 2 hours once-daily, followed by 20 days off. Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid orally in 14 days, followed by 7 days off Each drug will be continued until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends.

    Drug: ONO-4538 · Drug: Oxaliplatin · Drug: Tegafur- Gimeracil-Oteracil potassium

  • Experimental
    ONO-4538 + CapeOX Therapy Cohort (Part 1)

    ONO-4538 360 mg solution intravenously for 30 min in every 3 weeks. Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off. Capecitabine 1200 - 2100 mg bid orally in 14 days, followed by 7 days off. Each drug will be continued until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends.

    Drug: ONO-4538 · Drug: Oxaliplatin · Drug: Capecitabine

  • Experimental
    ONO-4538 + chemotherapy group (Part 2)

    With regard to the ONO-4538 + chemotherapy group, either SOX therapy or CapeOX therapy will be selected as the chemotherapy by the investigator or the subinvestigator, taking into account the condition of each subject. ONO-4538 360 mg solution intravenously for 30 min in every 3 weeks. Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off. Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid or Capecitabine 1000 mg/ m2 (body surface area) bid orally in 14 days, followed by 7 days off. Each drug will be continued until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends.

    Drug: ONO-4538 · Drug: Oxaliplatin · Drug: Tegafur- Gimeracil-Oteracil potassium · Drug: Capecitabine

  • Placebo comparator
    Placebo + Chemotherapy group (Part 2)

    With regard to the placebo + chemotherapy group, either SOX therapy or CapeOX therapy will be selected as the chemotherapy by the investigator or the subinvestigator, taking into account the condition of each subject. Placebo solution intravenously for 30 min in every 3 weeks. Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off. Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid or Capecitabine 1000 mg/ m2 (body surface area) bid orally in 14 days, followed by 7 days off. Each drug will be continued until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends.

    Drug: Oxaliplatin · Drug: Tegafur- Gimeracil-Oteracil potassium · Drug: Capecitabine · Drug: Placebo

06

What researchers measure

Primary outcomes

  1. Progression-free survival (central assessment by IRRC) (only Part 2)

    Time frame: Up to study completion (estimated time frame: 48 months)

  2. Overall survival (only Part 2)

    Time frame: Up to study completion (estimated time frame: 54 months)

Secondary outcomes

  1. Objective response rate (only Part 2)

    Time frame: Up to study completion (estimated time frame: 54 months)

  2. Progression-free survival (assessment by the site investigator)(only Part 2)

    Time frame: Up to study completion (estimated time frame: 54 months)

  3. Duration of response (only Part 2)

    Time frame: Up to study completion (estimated time frame: 54 months)

  4. Disease control rate (only Part 2)

    Time frame: Up to study completion (estimated time frame: 54 months)

  5. Time to response (only Part 2)

    Time frame: Up to study completion (estimated time frame: 54 months)

  6. Best overall response (only Part 2)

    Time frame: Up to study completion (estimated time frame: 54 months)

  7. Percent change in the sum of diameters of target lesions (only Part 2)

    Time frame: Up to study completion (estimated time frame: 54 months)

  8. Safety will be analyzed through the incidence of adverse events, serious adverse events

    Time frame: Up to 28 days from last dose

  9. Safety will be analyzed through the incidence of laboratory abnormalities

    Time frame: Up to 28 days from last dose

07

Study locations

130 sites
  • Aichi Clinical Site
    Nagoya, Aichi, Japan
  • Aomori Clinical Site
    Hirosaki, Aomori, Japan
  • Aomori Clinical Site
    Misawa, Aomori, Japan
  • Chiba Clinical Site
    Funabashi, Chiba, Japan
  • Chiba Clinical Site
    Kamogawa, Chiba, Japan
  • Chiba Clinical Site
    Kashiwa, Chiba, Japan
  • Ehime Clinical Site1
    Matsuyama, Ehime, Japan
  • Ehime Clinical Site2
    Matsuyama, Ehime, Japan
  • Fukuoka Clinical Site
    Iizuka, Fukuoka, Japan
  • Fukuoka Clinical Site1
    Kitakyushu, Fukuoka, Japan
  • Fukuoka Clinical Site2
    Kitakyushu, Fukuoka, Japan
  • Fukuoka Clinical Site
    Kurume, Fukuoka, Japan
  • Gifu Clinical Site
    Gifu-shi, Gifu, Japan
  • Gifu Clinical Site
    Ogaki, Gifu, Japan
  • Gumma Clinical Site
    Maebashi, Gumma, Japan
  • Gumma Clinical Site
    Takasaki, Gumma, Japan
  • Gunma Clinical Site
    Ota, Gunma, Japan
  • Hiroshima Clinical Site
    Kure, Hiroshima, Japan
  • Hokkaido Clinical Site
    Hakodate, Hokkaido, Japan
  • Hokkaido Clinical Site4
    Sapporo-shi, Hokkaido, Japan
  • Hokkaido Clinical Site1
    Sapporo, Hokkaido, Japan
  • Hokkaido Clinical Site2
    Sapporo, Hokkaido, Japan
  • Hokkaido Clinical Site3
    Sapporo, Hokkaido, Japan
  • Hyogo Clinical Site
    Akashi, Hyogo, Japan
  • Hyogo Clinical Site
    Amagasaki, Hyogo, Japan
  • Hyogo Clinical Site
    Kobe, Hyogo, Japan
  • Hyogo Clinical Site
    Nishinomiya, Hyogo, Japan
  • Ibaraki Clinical Site
    Higashiibaraki-gun, Ibaraki, Japan
  • Ibaraki Clinical Site
    Tsuchiura-shi, Ibaraki, Japan
  • Ishikawa Clinical Site1
    Kanazawa, Ishikawa, Japan
  • Ishikawa Clinical Site2
    Kanazawa, Ishikawa, Japan
  • Iwate Clinical Site
    Morioka, Iwate, Japan
  • Kagawa Clinical Site
    Kita-gun, Kagawa, Japan
  • Kanagawa Clinical Site
    Isehara, Kanagawa, Japan
  • Kanagawa Clinical Site
    Kamakura, Kanagawa, Japan
  • Kanagawa Clinical Site
    Sagamihara, Kanagawa, Japan
  • Kanagawa Clinical Site1
    Yokohama, Kanagawa, Japan
  • Kanagawa Clinical Site2
    Yokohama, Kanagawa, Japan
  • Kanagawa Clinical Site3
    Yokohama, Kanagawa, Japan
  • Miyagi Clinical Site
    Natori, Miyagi, Japan
  • Miyagi Clinical Site
    Osaki, Miyagi, Japan
  • Miyagi Clinical Site
    Sendai-shi, Miyagi, Japan
  • Nagano Clinical Site
    Saku, Nagano, Japan
  • Nara Clinical Site
    Ikoma, Nara, Japan
  • Nara Clinical Site
    Kashihara-shi, Nara, Japan
  • Okayama Clinical Site
    Kurashiki, Okayama, Japan
  • Osaka Clinical Site
    Izumi, Osaka, Japan
  • Osaka Clinical Site
    Osakasayama, Osaka, Japan
  • Osaka Clinical Site
    Sakai, Osaka, Japan
  • Osaka Clinical Site
    Suita, Osaka, Japan
  • Osaka Clinical Site
    Takatsuki, Osaka, Japan
  • Osaka Clinical Site
    Toyonaka, Osaka, Japan
  • Saitama Clinical Site
    Hidaka, Saitama, Japan
  • Saitama Clinical Site
    Kitaadachi-gun, Saitama, Japan
  • Shizuoka Clinical Site
    Hamamatsu-shi, Shizuoka, Japan
  • Tochigi Clinical Site
    Shimotsuke, Tochigi, Japan
  • Tochigi Clinical Site
    Utsunomiya, Tochigi, Japan
  • Tokyo Clinical Site
    Bunkyo-ku, Tokyo, Japan
  • Tokyo Clinical Site
    Chuo-ku, Tokyo, Japan
  • Tokyo Clinical Site
    Fuchu, Tokyo, Japan
  • Tokyo Clinical Site
    Koto-ku, Tokyo, Japan
  • Tokyo Clinical Site
    Minato-ku, Tokyo, Japan
  • Tokyo Clinical Site
    Shinagawa-ku, Tokyo, Japan
  • Tokyo Clinical Site1
    Shinjuku-ku, Tokyo, Japan
  • Tokyo Clinical Site2
    Shinjuku-ku, Tokyo, Japan
  • Tokyo Clinical Site
    Tachikawa, Tokyo, Japan
  • Tottori Clinical Site
    Yonago, Tottori, Japan
  • Yamagata Clinical Site
    Sakata, Yamagata, Japan
  • Akita Clinical Site
    Akita, Japan
  • Chiba Clinical Site1
    Chiba, Japan
  • Chiba Clinical Site2
    Chiba, Japan
  • Fukui Clinical Site
    Fukui, Japan
  • Fukuoka Clinical Site1
    Fukuoka, Japan
  • Fukuoka Clinical Site2
    Fukuoka, Japan
  • Fukuoka Clinical Site3
    Fukuoka, Japan
  • Fukuoka Clinical Site4
    Fukuoka, Japan
  • Fukushima Clinical Site
    Fukushima, Japan
  • Hiroshima Clinical Site1
    Hiroshima, Japan
  • Hiroshima Clinical Site2
    Hiroshima, Japan
  • Hiroshima Clinical Site3
    Hiroshima, Japan
  • Kumamoto Clinical Site1
    Kumamoto, Japan
  • Kumamoto Clinical Site2
    Kumamoto, Japan
  • Kumamoto Clinical Site3
    Kumamoto, Japan
  • Kyoto Clinical Site1
    Kyoto, Japan
  • Kyoto Clinical Site2
    Kyoto, Japan
  • Kyoto Clinical Site3
    Kyoto, Japan
  • Niigata Clinical Site
    Niigata, Japan
  • Okayama Clinical Site
    Okayama, Japan
  • Osaka Clinical Site1
    Osaka, Japan
  • Osaka Clinical Site2
    Osaka, Japan
  • Osaka Clinical Site3
    Osaka, Japan
  • Osaka Clinical Site4
    Osaka, Japan
  • Shizuoka Clinical Site
    Shizuoka, Japan
  • Tokushima Clinical Site
    Tokushima, Japan
  • Toyama Clinical Site
    Toyama, Japan
  • Wakayama Clinical Site
    Wakayama, Japan
  • Yamagata Clinical Site
    Yamagata, Japan
  • Busan Clinical Site
    Busan, Korea, Republic of
  • Daegu Clinical Site 1
    Daegu, Korea, Republic of
  • Daegu Clinical Site 2
    Daegu, Korea, Republic of

Showing the first 100 of 130 sites across 3 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Kang YK, Chen LT, Ryu MH, Oh DY, Oh SC, Chung HC, Lee KW, Omori T, Shitara K, Sakuramoto S, Chung IJ, Yamaguchi K, Kato K, Sym SJ, Kadowaki S, Tsuji K, Chen JS, Bai LY, Oh SY, Choda Y, Yasui H, Takeuchi K, Hirashima Y, Hagihara S, Boku N. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022 Feb;23(2):234-247. doi: 10.1016/S1470-2045(21)00692-6. Epub 2022 Jan 11. PubMed 35030335 ↗
  • Boku N, Ryu MH, Kato K, Chung HC, Minashi K, Lee KW, Cho H, Kang WK, Komatsu Y, Tsuda M, Yamaguchi K, Hara H, Fumita S, Azuma M, Chen LT, Kang YK. Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4). Ann Oncol. 2019 Feb 1;30(2):250-258. doi: 10.1093/annonc/mdy540. PubMed 30566590 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2016 to primary completion in Jan 2020, 46 months.

Of 26 phase 2/3 interventional studies under Stomach Neoplasms, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 52. This study's 46 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2016
First posted
Apr 21, 2016
StartActual
Mar 2016
Primary completionActual
Jan 2020
CompletionActual
Nov 17, 2022
Last update
May 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02746796
Responsible party
Sponsor
First posted
Apr 21, 2016
Start date
Mar 2016
Primary completion
Jan 2020
Completion
Nov 17, 2022
Last update
May 3, 2024

Study contacts

Mitsunobu Tanimoto
study director · Ono Pharmaceutical Co. Ltd

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Tegafur-gimeracil-oteracil · Capecitabine

Start the discussion